Exelixis, Inc.is a biopharmaceutical company.
Advertisement
Exelixis Inc has 230,325,000 shares which are now outstanding with a price of 13.01 calculating Exelixis Inc’s market capitalisation to 3.00B Dollars.
Exelixis, Inc. NASDAQ:EXEL has a 50 day moving average of 10.38 Dollars and the 200 Day Moving Average price is recorded at 6.54 USD. (NASDAQ: EXEL) now has a 50-day MA is $10.69 and 200-day MA is $6.97, and it has traded in a 52-week range between $3.55 – 12.48 and the last closing price is -1.36 percent off the 52 week high.
Investors evaluating EXEL stock at the current market price of $12.31/share should know the company will next release quarterly results for the September 2016 quarter. Company shares were Reiterated by Stifel on Aug 4, 2016 to “Buy”, Firm has raised the Price Target to $ 12 from a previous price target of $10.Company shares were Reiterated by Leerink Partners on Jun 21, 2016 to “Outperform”, Firm has raised the Price Target to $ 10 from a previous price target of $8. The shares ended last trade at $12.31, implying that Wall Street analysts see shares losing about -13.32 per cent in 12 months’ time. However a year ago during same quarter Exelixis, Inc.
Exelixis (NASDAQ:EXEL) opened at 13.01 on Thursday. Analyst forecasts, earnings estimates and price target projections are issued to help their clients make money through stock investments. According to a research note published on Sep 2, 2014, analysts at Stifel have lowered their rating on the company stock from Buy to Hold. (NASDAQ:EXEL) to report earnings of about $0.06 per share on $1,050.32M in revenue.
EXEL is ahead its 52-week low with 272.11%and going up from its 52-week high price with 0.15%. It has been assigned a low target price of $7 and a high target price of $15. The stock stands almost $0.83 off versus the 52-week high of $7.08 and $3.64 above the 52-week low of $2.61. The insider owns 9,055,671 shares which have current market value of around $117814280.HARF PETER is another major inside shareholder in the company. This number is based on a scale from 1 to 5. “1” issued rating as a “HOLD”. 4 of the brokerages firms have a buy or better rating; the 0 sells versus 0 underperforms.
Over the past five trading sessions shares of Agenus Inc. The count of Hold ratings in that period was 0. The average volume stands around 5.9 million shares.
Advertisement
Insider Activity: Corporate insiders look pessimistic about the outlook of the company stock that they seem to offload shares while they have 118.26 jumped so far this year.
